|
| 36855819 | Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug. | CPT Pharmacometrics Syst Pharmacol | 2023 |
| 36855819 | Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug. | CPT Pharmacometrics Syst Pharmacol | 2023 |
| 34862964 | Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective. | Clin Pharmacol Ther | 2022 |
| 35570332 | Robust physiologically based pharmacokinetic model of rifampicin for predicting drug-drug interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidney. | CPT Pharmacometrics Syst Pharmacol | 2022 |
| 35561140 | Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective. | Clin Pharmacol Ther | 2022 |
| 35421902 | Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs. | Clin Transl Sci | 2022 |
| 34862964 | Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective. | Clin Pharmacol Ther | 2022 |
| 35292967 | Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions. | Clin Pharmacol Ther | 2022 |
| 35570332 | Robust physiologically based pharmacokinetic model of rifampicin for predicting drug-drug interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidney. | CPT Pharmacometrics Syst Pharmacol | 2022 |
| 35421902 | Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs. | Clin Transl Sci | 2022 |
| 35561140 | Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective. | Clin Pharmacol Ther | 2022 |
| 35292967 | Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions. | Clin Pharmacol Ther | 2022 |
| 32460379 | Intestinal P-gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications. | Clin Pharmacol Ther | 2021 |
| 32460379 | Intestinal P-gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications. | Clin Pharmacol Ther | 2021 |
| 33991429 | Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program. | Clin Pharmacol Ther | 2021 |
| 33759451 | When special populations intersect with drug-drug interactions: Application of physiologically-based pharmacokinetic modeling in pregnant populations. | Biopharm Drug Dispos | 2021 |
| 33397250 | Physiologically-based Pharmacokinetic (PBPK) Modelling of Transporter Mediated Drug Absorption, Clearance and Drug-drug Interactions. | Curr Drug Metab | 2021 |
| 33759451 | When special populations intersect with drug-drug interactions: Application of physiologically-based pharmacokinetic modeling in pregnant populations. | Biopharm Drug Dispos | 2021 |
| 33991429 | Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program. | Clin Pharmacol Ther | 2021 |
| 33397250 | Physiologically-based Pharmacokinetic (PBPK) Modelling of Transporter Mediated Drug Absorption, Clearance and Drug-drug Interactions. | Curr Drug Metab | 2021 |
| 31628859 | Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations. | Clin Pharmacol Ther | 2020 |
| 32009006 | Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations. | Drug Metab Dispos | 2020 |
| 31628859 | Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations. | Clin Pharmacol Ther | 2020 |
| 32009006 | Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations. | Drug Metab Dispos | 2020 |
| 31167838 | Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways. | Drug Metab Dispos | 2019 |
| 31167838 | Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways. | Drug Metab Dispos | 2019 |
| 28560712 | Endogenous Probes for Drug Transporters: Balancing Vision With Reality. | Clin Pharmacol Ther | 2018 |
| 28560712 | Endogenous Probes for Drug Transporters: Balancing Vision With Reality. | Clin Pharmacol Ther | 2018 |
| 30137645 | Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective. | Clin Pharmacol Ther | 2018 |
| 30137645 | Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective. | Clin Pharmacol Ther | 2018 |
| 28469522 | Unmasking the Role of Uptake Transporters for Digoxin Uptake Across the Barriers of the Central Nervous System in Rat. | J Cent Nerv Syst Dis | 2017 |
| 28469522 | Unmasking the Role of Uptake Transporters for Digoxin Uptake Across the Barriers of the Central Nervous System in Rat. | J Cent Nerv Syst Dis | 2017 |
| 27541873 | Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer. | Pharm Res | 2016 |
| 27385177 | Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites. | J Clin Pharmacol | 2016 |
| 27541873 | Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer. | Pharm Res | 2016 |
| 27385177 | Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites. | J Clin Pharmacol | 2016 |
| 24380373 | Estimation of the unbound brain concentration of P-glycoprotein substrates or nonsubstrates by a serial cerebrospinal fluid sampling technique in rats. | Mol Pharm | 2014 |
| 24380373 | Estimation of the unbound brain concentration of P-glycoprotein substrates or nonsubstrates by a serial cerebrospinal fluid sampling technique in rats. | Mol Pharm | 2014 |
| 22011930 | Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. | Pharm Res | 2012 |
| 22011930 | Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. | Pharm Res | 2012 |
| 20829328 | Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. | Clin Cancer Res | 2010 |
| 20829328 | Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. | Clin Cancer Res | 2010 |
| 19774344 | Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. | Pharm Res | 2009 |
| 19789319 | Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. | Clin Cancer Res | 2009 |
| 19774344 | Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. | Pharm Res | 2009 |
| 19789319 | Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. | Clin Cancer Res | 2009 |